News

Myasthenia gravis (MG) can have a substantial impact on a person’s quality of life, but currently available data make it hard to nail down a number that can represent the average impact of the disease in standard health economic models, a review study showed. Score estimates in the EuroQol…

Adults with late-onset myasthenia gravis (LOMG), when symptoms begin at age 50 or later, showed advanced fatty replacement of the thymus gland, while a separate group of LOMG patients showed reduced production of new immune cells, according to a new study. Abnormalities in the thymus gland are well established…

Myasthenia gravis (MG) is associated with substantial disruptions to employment, with only about half of working-age adults with MG in a Spanish study employed and nearly one-third receiving permanent work disability benefits. Among participants who reported how MG had affected their employment, more than four in 10 said they…

Myasthenia gravis (MG) may be driven by antibody-producing immune B-cells going rogue in the thymus gland and developing escape mechanisms that allow them to attack the body’s own healthy tissues, according to new research by U.S. scientists. “Our study suggests there’s more to myasthenia gravis than antibodies alone,” Ankit…

Uplizna (inebilizumab) reduced the frequency of disease exacerbations, or periods when symptoms worsen, and the need for rescue therapy in people with generalized myasthenia gravis (gMG). That’s according to a prespecified analysis of data from the global Phase 3 MINT clinical trial (NCT04524273), which showed that after…

Myasthenia gravis (MG) is the strongest predictor of complications after a thymectomy, a surgery to remove a tumor of the thymus gland, according to a study in China. The risk of post-surgery complications was more than seven times higher in people with MG. Other factors independently associated with complication…

Vyvgart (efgartigimod alfa-fcab), an approved treatment for myasthenia gravis (MG), can quickly and safely ease symptoms in people with the rare neuromuscular disease who are experiencing severe flare-ups, a new study suggests. Although the study was limited to a small number of patients, the researchers said the data…

Top-line results — a snapshot of key early findings — from a large international clinical trial testing Immunovant’s therapy candidate IMVT-1402 in adults with generalized myasthenia gravis (gMG) are expected next year, according to the developer. The trial, involving an estimated 231 participants at 88 locations worldwide, is…

In a global late-stage trial testing gefurulimab for generalized myasthenia gravis (gMG), the injection treatment candidate was shown to safely and effectively ease gMG symptoms — per both patient-reported and physician-rated scales. That’s according to the final results from this Phase 3 clinical trial, called PREVAIL (NCT05556096),…

Different forms of myasthenia gravis (MG) may have distinct patterns of immune system activity, with MG that appears before age 50 and MG driven by antibodies against the muscle-specific kinase (MuSK) protein showing stronger activity, a study found. “These findings underscore the immunological [variability] of MG and suggest that…